Related Experiment Videos
Erythromycin associated hearing loss in a patient with prior cis-platinum induced ototoxicity
P M Wallach1, S R Love, J V Fiorica
1Department of Internal Medicine, University of South Florida College of Medicine, Tampa.
The Journal of the Florida Medical Association
|December 1, 1992
Abstract:
A case is reported of reversible sensorineural hearing loss associated with intravenous erythromycin treatment. Cis-platinum induced high frequency hearing loss developed nine months previously during treatment for stage IV papillary cystadenocarcinoma. Renal and hepatic function were normal; however, serum erythromycin levels were elevated. Clinical recovery promptly followed discontinuation of erythromycin.